This Article Full Text Full Text (PDF) All Versions of this Article: 101/12/1266    most recent CIRCRESAHA.107.156380v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, P. Articles by Redwood, C. S. Search for Related Content PubMed PubMed Citation Articles by Robinson, P. Articles by Redwood, C. S. Related Collections Contractile function Cell signalling/signal transduction Myocardial cardiomyopathy disease

(Circulation Research. 2007;101:1266.)
© 2007 American Heart Association, Inc.

Cellular Biology

Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and -Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments

Paul Robinson, Peter J. Griffiths, Hugh Watkins, Charles S. Redwood

From the Departments of Cardiovascular Medicine (P.R., H.W., C.S.R.) and Physiology, Anatomy and Genetics (P.J.G.), University of Oxford, United Kingdom.

Correspondence to Dr Charles Redwood, Department of Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre of Human Genetics, Oxford OX3 7BN, United Kingdom. E-mail credwood{at}well.ox.ac.uk

Dilated cardiomyopathy and hypertrophic cardiomyopathy (HCM) can be caused by mutations in thin filament regulatory proteins of the contractile apparatus. In vitro functional assays show that, in general, the presence of dilated cardiomyopathy mutations decreases the Ca²⁺ sensitivity of contractility, whereas HCM mutations increase it. To assess whether this functional phenomenon was a direct result of altered Ca²⁺ affinity or was caused by altered troponin–tropomyosin switching, we assessed Ca²⁺ binding of the regulatory site of cardiac troponin C in wild-type or mutant troponin complex and thin filaments using a fluorescent probe (2-[4'-{iodoacetamido}aniline]-naphthalene-6-sulfonate) attached to Cys35 of cardiac troponin C. The Ca²⁺-binding affinity (pCa₅₀=6.57±0.03) of reconstituted troponin complex was unaffected by all of the HCM and dilated cardiomyopathy troponin mutants tested, with the exception of the troponin I Arg145Gly HCM mutation, which caused an increase (pCa₅₀=+0.31±0.05). However, when incorporated into regulated thin filaments, all but 1 of the 10 troponin and -tropomyosin mutants altered Ca²⁺-binding affinity. Both HCM mutations increased Ca²⁺ affinity (pCa₅₀=+0.41±0.02 and +0.51±0.01), whereas the dilated cardiomyopathy mutations decreased affinity (pCa₅₀=–0.12±0.04 to –0.54±0.04), which correlates with our previous functional in vitro assays. The exception was the troponin T Asp270Asn mutant, which caused a significant decrease in cooperativity. Because troponin is the major Ca²⁺ buffer in the cardiomyocyte sarcoplasm, we suggest that Ca²⁺ affinity changes caused by cardiomyopathy mutant proteins may directly affect the Ca²⁺ transient and hence Ca²⁺-sensitive disease state remodeling pathways in vivo. This represents a novel mechanism for this class of mutation.

Key Words: cardiomyopathy • calcium • troponin • signaling

This article has been cited by other articles:

				R. Aguilar-Torres Found in translation: metoprolol improves survival more than carvedilol in a mouse model of inherited dilated cardiomyopathy Cardiovasc Res, October 1, 2009; 84(1): 7 - 8. [Full Text] [PDF]

				E. C. Dyer, A. M. Jacques, A. C. Hoskins, D. G. Ward, C. E. Gallon, A. E. Messer, J. P. Kaski, M. Burch, J. C. Kentish, and S. B. Marston Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle Circ Heart Fail, September 1, 2009; 2(5): 456 - 464. [Abstract] [Full Text] [PDF]

				S. Carballo, P. Robinson, R. Otway, D. Fatkin, J. D.H. Jongbloed, N. de Jonge, E. Blair, J. P. van Tintelen, C. Redwood, and H. Watkins Identification and Functional Characterization of Cardiac Troponin I As a Novel Disease Gene in Autosomal Dominant Dilated Cardiomyopathy Circ. Res., August 14, 2009; 105(4): 375 - 382. [Abstract] [Full Text] [PDF]

				R. E. Hershberger, J. R. Pinto, S. B. Parks, J. D. Kushner, D. Li, S. Ludwigsen, J. Cowan, A. Morales, M. S. Parvatiyar, and J. D. Potter Clinical and Functional Characterization of TNNT2 Mutations Identified in Patients With Dilated Cardiomyopathy Circ Cardiovasc Genet, August 1, 2009; 2(4): 306 - 313. [Abstract] [Full Text] [PDF]

				J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, M. J. Ackerman, and J. D. Potter A Functional and Structural Study of Troponin C Mutations Related to Hypertrophic Cardiomyopathy J. Biol. Chem., July 10, 2009; 284(28): 19090 - 19100. [Abstract] [Full Text] [PDF]

				S. J. van Dijk, D. Dooijes, C. dos Remedios, M. Michels, J. M.J. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F. J. ten Cate, G. J.M. Stienen, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction Circulation, March 24, 2009; 119(11): 1473 - 1483. [Abstract] [Full Text] [PDF]

				D. Dweck, N. Hus, and J. D. Potter Challenging Current Paradigms Related to Cardiomyopathies: ARE CHANGES IN THE Ca2+ SENSITIVITY OF MYOFILAMENTS CONTAINING CARDIAC TROPONIN C MUTATIONS (G159D AND L29Q) GOOD PREDICTORS OF THE PHENOTYPIC OUTCOMES? J. Biol. Chem., November 28, 2008; 283(48): 33119 - 33128. [Abstract] [Full Text] [PDF]

				R. Lombardi, A. Bell, V. Senthil, J. Sidhu, M. Noseda, R. Roberts, and A. J. Marian Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies Cardiovasc Res, July 1, 2008; 79(1): 109 - 117. [Abstract] [Full Text] [PDF]

				J. P. Davis and S. B. Tikunova Ca2+ exchange with troponin C and cardiac muscle dynamics Cardiovasc Res, March 1, 2008; 77(4): 619 - 626. [Abstract] [Full Text] [PDF]